Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were up 5.3% on Monday following a better than expected earnings announcement. The stock traded as high as $2.05 and last traded at $2.00, with a volume of 1,748,720 shares traded. The stock had previously closed at $1.90.

The specialty pharmaceutical company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.49. BioDelivery Sciences International had a negative return on equity of 1.45% and a negative net margin of 0.19%. The firm had revenue of $29.48 million during the quarter, compared to analyst estimates of $27.07 million.

Several equities research analysts have recently issued reports on BDSI shares. Zacks Investment Research lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Tuesday, March 14th. ValuEngine lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. Roth Capital set a $5.00 target price on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Wednesday, March 22nd. FBR & Co reaffirmed a “buy” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a research report on Monday, March 20th. Finally, HC Wainwright started coverage on BioDelivery Sciences International in a research report on Friday, May 26th. They set a “buy” rating and a $4.00 target price for the company. Three equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $3.71.

In related news, CEO Mark A. Sirgo sold 110,895 shares of BioDelivery Sciences International stock in a transaction dated Friday, March 31st. The stock was sold at an average price of $1.90, for a total value of $210,700.50. Following the completion of the sale, the chief executive officer now owns 1,670,157 shares of the company’s stock, valued at approximately $3,173,298.30. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last three months, insiders sold 112,345 shares of company stock valued at $213,456. 9.00% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new stake in shares of BioDelivery Sciences International during the fourth quarter valued at $142,000. Searle & CO. raised its stake in shares of BioDelivery Sciences International by 27.1% in the fourth quarter. Searle & CO. now owns 234,100 shares of the specialty pharmaceutical company’s stock valued at $410,000 after buying an additional 49,850 shares during the period. Oxford Asset Management raised its stake in shares of BioDelivery Sciences International by 280.8% in the fourth quarter. Oxford Asset Management now owns 107,945 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 79,599 shares during the period. Broadfin Capital LLC raised its stake in shares of BioDelivery Sciences International by 4.0% in the fourth quarter. Broadfin Capital LLC now owns 5,398,794 shares of the specialty pharmaceutical company’s stock valued at $9,448,000 after buying an additional 210,000 shares during the period. Finally, Blair William & Co. IL raised its stake in shares of BioDelivery Sciences International by 37.6% in the first quarter. Blair William & Co. IL now owns 693,181 shares of the specialty pharmaceutical company’s stock valued at $1,386,000 after buying an additional 189,484 shares during the period. 40.32% of the stock is owned by institutional investors.

The firm has a 50 day moving average of $2.13 and a 200 day moving average of $1.93. The stock’s market capitalization is $127.25 million.

ILLEGAL ACTIVITY NOTICE: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/06/16/biodelivery-sciences-international-inc-bdsi-shares-up-5-3-on-strong-earnings-updated-updated.html.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.